Benzinga's Top #PreMarket Gainers

shares gained 39.24% to $40.70 in the pre-market trading session on news that the company's Phase I study of its treatment for Parkinson's disease met its primary end point for safety.

shares climbed 17.69% to $54.30 in pre-market trading after the company reported a narrower-than-expected loss for the fourth quarter.

shares rose 7.10% to $309.00 in pre-market trading on positive Phase 2b Flint trial data.

shares surged 5.85% to $459.00 in pre-market trading on positive Alzheimer's study results.

gained 3.74% to $102.00 in pre-market trading after the company reported better-than-expected earnings for its fiscal third quarter.